A cost-effectiveness analysis of a new and more effective treatment for unresectable hepatocellular carcinoma—from a Chinese perspective
Jianhua Chen, Zuojun Dong, Bingchao Shou, Zimeng Huang, Li Huang, Guojun Sun · 2025
Read A cost-effectiveness analysis of a new and more effective treatment for unresectable hepatocellular carcinoma—from a Chinese perspective by Jianhua Chen, Zuojun Dong, Bingchao Shou, Zimeng Huang, Li Huang, Guojun Sun (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12687885.txt.
Description
A liver cancer that cannot be cut out needs drugs, and new drugs must prove they are worth their price. Jianhua Chen and co-authors weigh a drug pair against the standard drug for this cancer in a 2025 study, from a Chinese health system view. The pair joins anlotinib with an immune drug, penpulimab.
Their model runs the disease over ten years in three-week steps. The pair cost about 11,191 dollars more and bought 0.56 years of good-quality life. That price per year fell well under the set limit of three times national income per person. Repeated checks with varied inputs kept the same verdict. The authors call the pair good value for China.
Catalog record
| CREATOR | Jianhua Chen, Zuojun Dong, Bingchao Shou, Zimeng Huang, Li Huang, Guojun Sun |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |